|
Volumn 13, Issue 5, 2004, Pages 33-37
|
Clinical role of LDL and HDL subclasses and apolipoprotein measurement
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTILIPEMIC AGENT;
APOLIPOPROTEIN;
APOLIPOPROTEIN B;
BIOCHEMICAL MARKER;
FIBRIC ACID DERIVATIVE;
GEMFIBROZIL;
HIGH DENSITY LIPOPROTEIN;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LIPID;
LOW DENSITY LIPOPROTEIN;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
NICOTINIC ACID;
ATHEROGENESIS;
ATHEROSCLEROSIS;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
CORRELATION ANALYSIS;
DRUG EFFICACY;
HUMAN;
LIPID ANALYSIS;
LIPID BLOOD LEVEL;
METABOLIC SYNDROME X;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;
PARTICLE SIZE;
PREDICTION;
PROGNOSIS;
REVIEW;
RISK ASSESSMENT;
TREATMENT PLANNING;
|
EID: 3042814423
PISSN: 10621458
EISSN: None
Source Type: Journal
DOI: 10.1016/j.accreview.2004.04.095 Document Type: Review |
Times cited : (18)
|
References (12)
|